Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02035813
Recruitment Status : Recruiting
First Posted : January 14, 2014
Last Update Posted : October 25, 2019
Sponsor:
Information provided by (Responsible Party):
Prof. W. Janni, University of Ulm

Tracking Information
First Submitted Date  ICMJE January 12, 2014
First Posted Date  ICMJE January 14, 2014
Last Update Posted Date October 25, 2019
Study Start Date  ICMJE January 2014
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 13, 2014)
Progression free survival (PFS) [ Time Frame: 8-12 weeks ]
Time interval from randomization until progressive disease (PD) or death from any cause, whichever comes first
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 23, 2019)
  • Overall response rate [ Time Frame: 8-12 weeks ]
    Rate of complete (CR) and partial responses (PR) in patients with whom target lesions were defined
  • Disease control rate (DCR) [ Time Frame: 8-12 weeks ]
    rate of patients who were assessed as having a PR or a CR or who had stable disease (SD) for at least 6 months
  • Overall survival (OS) [ Time Frame: 4 weeks ]
    Time from randomization until death of any cause
  • Dynamic of CTCs [ Time Frame: 8-12 weeks ]
    Descriptive statistics of regular CTC counts
  • For Everolimus/Ribociclib cohort only: Levels of pS6 [ Time Frame: 8-12 weeks ]
    Descriptive statistics of pS6 levels at baseline, at first radiological tumor assessment after about 12 weeks, and at the time of progression
  • For Everolimus/Ribociclib cohort only: Change in the activation of the PI3K/Akt/mTOR-pathway in CTCs [ Time Frame: 8-12 weeks ]
    Descriptive statistics of changes in the activation of the PI3K/Akt/mTOR-pathway in CTCs as assessed by longitudinal comparisons (at baseline, after 12 weeks, at time of progression)
  • For Everolimus/Ribociclib cohort only: Estrogen-receptor 1 (ESR-1) mutations in CTCs [ Time Frame: 8-12 weeks ]
    Estrogen-receptor 1 (ESR-1) mutations in CTCs at baseline, after 12 weeks and at time of progression
  • For Eribulin cohort only: New metastasis-free survival (nMFS) [ Time Frame: 8-12 weeks ]
    New metastasis-free survival (nMFS), defined as time from recruitment to death or progression due to appearance of a new metastasis, whichever comes first. If a patient has not had an event, nMFS is censored at the date of last adequate tumor as-sessment
Original Secondary Outcome Measures  ICMJE
 (submitted: January 13, 2014)
  • Overall response rate [ Time Frame: 8-12 weeks ]
    Rate of complete (CR) and partial responses (PR) in patients with whom target lesions were defined
  • Disease control rate (DCR) [ Time Frame: 8-12 weeks ]
    rate of patients who were assessed as having a PR or a CR or who had stable disease (SD) for at least 6 months
  • Overall survival (OS) [ Time Frame: 4 weeks ]
    Time from randomization until death of any cause
  • Dynamic of CTCs [ Time Frame: 8-12 weeks ]
    Descriptive statistics of regular CTC counts
  • Levels of pS6 [ Time Frame: 8-12 weeks ]
    Descriptive statistics of pS6 levels at baseline, at first radiological tumor assessment after about 12 weeks, and at the time of progression
  • Change in the activation of the PI3K/Akt/mTOR-pathway in CTCs [ Time Frame: 8-12 weeks ]
    Descriptive statistics of changes in the activation of the PI3K/Akt/mTOR-pathway in CTCs as assessed by longitudinal comparisons (at baseline, after 12 weeks, at time of progression)
  • Estrogen-receptor 1 (ESR-1) mutations in CTCs [ Time Frame: 8-12 weeks ]
    Estrogen-receptor 1 (ESR-1) mutations in CTCs at baseline, after 12 weeks and at time of progression
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Official Title  ICMJE DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Brief Summary Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
  • HER2-negative Circulating Tumor Cells
  • Postmenopausal Female Patients
Intervention  ICMJE
  • Drug: Ribociclib
    Ribociclib/Everolimus in combination with endocrine therapy
    Other Name: Kisqali
  • Drug: Eribulin
    Other Name: Halaven
Study Arms  ICMJE
  • Experimental: Ribociclib in combination with standard endocrine therapy
    Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
    Intervention: Drug: Ribociclib
  • Experimental: Eriubulin
    Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
    Intervention: Drug: Eribulin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 23, 2019)
300
Original Estimated Enrollment  ICMJE
 (submitted: January 13, 2014)
400
Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Both cohorts:

  • Indication for an endocrine therapy (Histological confirmation of estrogen receptor positive (ER+) and/or progesterone receptor positive (PgR+) breast cancer).
  • Up to two lines of previous cytostatic treatment for MBC.
  • Any endocrine therapy in the history is allowed.
  • Disease progression following prior treatment with endocrine therapy (endocrine therapy does not have to be the last therapy before inclusion in the trial).
  • Postmenopausal women. The investigator must confirm postmenopausal status Postmenopausal status is defined either by

    • Age ≥ 55 years and one year or more of amenorrhea
  • - Age < 55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH
  • - Prior hysterectomy and has postmenopausal levels of FSH and LH
  • - Surgical menopause with bilateral oophorectomy
  • Everolimus cohort:
  • Cholesterol ≤ 2.0 × ULN
  • Ribociclib cohort:
  • Standard 12-lead ECG values assessed by the local laboratory:
  • - QTcF interval at screening < 450 msec (using Fridericia's correction)
  • - Resting heart rate 50-90 bpm
  • INR ≤ 1,5 (ribocilclib cohort)
  • Patients must have the following laboratory values within normal limits or corrected to within normal lim-its with supplemets before the first dose of study medication:
  • -Sodium
  • -Potassium
  • -Total calcium

For Eribulin only:

  • Either hormone-receptor negative MBC or hormone-receptor positive MBC with indication for chemotherapy
  • Up to three previous chemotherapy treatment lines for metastatic disease
  • In case of patients of child bearing potential:

    • Negative pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) within 7 days prior to recruitment
    • Contraception by means of a reliable method (i.e. non-hormonal contraception, IUD, a dou-ble barrier method, vasectomy of the sexual partner, complete sexual abstinence). Patient must consent in maintaining such contracep-tion until 3 months after completion of study treatment

Exclusion Criteria:

In General for both study cohorts:

  1. Treatment with other investigational agents of any type or anticancer therapy during the trial, within 2 weeks prior to the start of treatment.
  2. Adverse events due to prior anticancer therapy which are > Grade 1 (NCI CTCAE) and therapeutically relevant at time of treatment start.
  3. Known HIV infection.
  4. Current active hepatitis B or C, cliniclally relevant known liver dysfunction, e.g. according to Child Pugh Classifica-tion class B and C, or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gall-stones, liver metastases or stable chronic non-viral liver disease per investigator assessment).
  5. Concurrent disease or condition that might interfere with adequate assessment or evaluation of study data, or any medical disorder that would make the patient's participation unreasonably hazardous.
  6. Other malignant diseases within the last 3 years (apart from carcinoma in situ of the cervix or non-melanoma skin cancer)
  7. Dementia, altered mental status, or any psychiatric or social condition which would prohibit the understanding or rendering of informed consent or which might interfere with the patient's adherence to the protocol.
  8. Life expectancy < 3 months.
  9. Male gender.

For Everolimus/Ribociclib only:

  • Known hypersensitivity to any of the excipients of ribociclib, everolimus or any of the other given drugs.
  • Known hypersensitivity to lecithin (soya) and pea-nuts (ribocilib-cohort)
  • Disease or condition, which might restrain the ability to take or resorb oral medication. This includes malabsorption syndrome, requirement for intrave-nous (IV) alimentation, prior surgical procedures af-fecting absorption (for example resection of small bowel or stomach), uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis) and any other diseases significantly affecting gas-trointestinal function as well as inability to swallow and retain oral medication for any other reason.

For Eribulin only:

  • History of hypersensitivity reactions attributed to eribulin.
  • Pre-existing neuropathy grade 3 or higher.
  • Severe Congenital long QT syndrome.
  • Pregnancy or nursing.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Sabrina Krause, M. sc. sabrina.krause@uniklinik-ulm.de
Contact: Fabienne Schochter, MD studienzentrale.ufk@uniklinik-ulm.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02035813
Other Study ID Numbers  ICMJE D-IV
2013-001269-18 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Prof. W. Janni, University of Ulm
Study Sponsor  ICMJE Prof. W. Janni
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Tanja Fehm, MD, PhD University Hospital Düsseldorf -Department of Gynecology
Study Director: Wolfgang Janni, MD, PhD University Hospital Ulm -Department of Gynecology
PRS Account University of Ulm
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP